View : 147 Download: 167

sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1 alpha signaling pathways

Title
sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1 alpha signaling pathways
Authors
Kim, Boh-RamSeo, Seung HeePark, Mi SunLee, Seung-HoonKwon, YoungjooRho, Seung Bae
Ewha Authors
권영주
SCOPUS Author ID
권영주scopus
Issue Date
2015
Journal Title
ONCOTARGET
ISSN
1949-2553JCR Link
Citation
ONCOTARGET vol. 6, no. 31, pp. 31830 - 31843
Keywords
sMEK1 tumor suppressor; hypoxic condition; anti-angiogenic activity; ovarian tumor; xenograft model
Publisher
IMPACT JOURNALS LLC
Indexed
SCIE; SCOPUS WOS
Document Type
Article
Abstract
The suppressor of MEK null (sMEK1) protein possesses pro-apoptotic activities. In the current study, we reveal that sMEK1 functions as a novel anti-angiogenic factor by suppressing vascular endothelial growth factor (VEGF)-induced cell proliferation, migration, and capillary-like tubular structure in vitro. In addition, sMEK1 inhibited the phosphorylation of the signaling components up-and downstream of Akt, including phospholipase C gamma 1 (PLC-gamma 1), 3-phosphoinositide-dependent protein kinase 1 (PDK1), endothelial nitric oxide synthetase (eNOS), and hypoxia-inducible factor 1 (HIF-1 alpha) during ovarian tumor progression via binding with vascular endothelial growth factor receptor 2 (VEGFR-2). Furthermore, sMEK1 decreased tumor vascularity and inhibited tumor growth in a xenograft human ovarian tumor model. These results supply convincing evidence that sMEK1 controls endothelial cell function and subsequent angiogenesis by suppressing VEGFR-2-mediated PI3K/Akt/eNOS signaling pathway. Taken together, our results clearly suggest that sMEK1 might be a novel anti-angiogenic and anti-tumor agent for use in ovarian tumor.
Appears in Collections:
약학대학 > 약학과 > Journal papers
Files in This Item:
001.pdf(1.29 MB) Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE